Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Robert Aris, MD

Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CCAssociate Professor of Medicine
University of North Carolina Chapel Hill - CC
Member of the Healthcare Council

Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic fibrosis, pulmonary hypertension, emphysema, pulmonary fibrosis, COPD, lung cancer, lung transplant, and asthma. He is also involved in critical care medicine managing patients with respiratory failure, shock, multiorgan failure, and sepsis. Dr. Aris' research interests include pulmonary hypertension, cystic fibrosis, basic immunology, clinical infectious diseases, post transplant malignancy and critical care. He has published over 75 articles and book chapters, chaired numerous symposia at national conferences, provides ad hoc peer review for over 25 journals (including all the major respiratory journals) and serves on the editorial board of numerous prestigious journals. (This is me - Update Profile)


Employment History
1993 - present Associate Professor of Medicine
University of North Carolina Chapel Hill - CC

GLG NewsSM Analyses by Robert Aris, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Mild PAH improved by early treatment with bosentan | 07-18-2008
Author: Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC

While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients.  This is important because the definition of functional class II is that a patient has a sight...

Peer reviewed literature on Ambrisentan, a selective ETRA for PAH | 06-10-2008
Author: Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC

This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...

GLG InstituteSM Seminars with Robert Aris, MD(?)

 
Robert Aris, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Robert Aris, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-04T21:45:16.757